Influenza virus H9N2 vaccine - Crucell

Drug Profile

Influenza virus H9N2 vaccine - Crucell

Latest Information Update: 03 Dec 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Influenza A virus H9N2 subtype

Most Recent Events

  • 03 Dec 2012 Janssen licenses the NanoPass MicronJet®, microneedle delivery device for use in its vaccine programmes
  • 14 Aug 2007 Crucell completes a phase I/II trial in the UK
  • 31 May 2006 Phase-I/II clinical trials in Influenza virus infections in United Kingdom (IM, Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top